已核实 DOI PubMed 相关产品: 13

Antitumor Effects of Pegylated Zinc Protoporphyrin-Mediated Sonodynamic Therapy in Ovarian Cancer

Journal 2023 · IF 5.4 · 15(9): 2275 · 发表于 2023 年 9 月 4 日
作者: Jia Li,Zheng Hu,Jiwei Zhu,Xin Lin,Xu Gao,Guixiang Lv
阅读全文 在 PubMed 查看

摘要

Sonodynamic therapy (SDT) induces reactive oxygen species (ROS) to kill tumor cells. Heme oxygenase-1 (HO-1), as an important antioxidant enzyme, resists killing by scavenging ROS. Zinc protoporphyrin (ZnPP) not only effectively inhibits HO-1 activity, but also becomes a potential sonosensitizer. However, its poor water solubility limits its applications. Herein, we developed an improved water-soluble method. It was proved that pegylated zinc protoporphyrin-mediated SDT (PEG-ZnPP-SDT) could significantly enhance ROS production by destroying the HO-1 antioxidant system in ovarian cancer. Increased ROS could cause mitochondrial membrane potential collapse, release cytochrome c from mitochondria to the cytoplasm, and trigger the mitochondrial–caspase apoptotic pathway. In conclusion, our results demonstrated that PEG-ZnPP-SDT, as a novel sonosensitizer, could improve the antitumor effects by destroying the HO-1 antioxidant system. It provided a new therapeutic strategy for SDT to treat cancers, especially those with higher HO-1 expression.Keywords:pegylated zinc protoporphyrin;sonodynamic therapy;reactive oxygen species;apoptosis;antitumor effects

本研究中使用的阿拉丁产品

13 款产品在本文中被引用